Clinical Trial Update: PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating extended dosing of PROCRIT (epoetin alfa) for maintaining hemoglobin in pre-dialysis chronic kidney disease patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• PROCRIT (ERYTHROPOIETIN)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Anemia, Renal Diseases | Phase 3 | Status: COMPLETED | Results posted: 2011-04-14